-
Mashup Score: 41Surgical Outcomes with Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC - 4 day(s) ago
In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival and pathological complete response (primary endpoints; modified ITT [mITT] population, which excluded patients with known EGFR/ALK aberrations) with a manageable safety profile in patients with resectable (R)-NSCLC. Here, we report surgical outcomes from AEGEAN.
Source: www.jto.orgCategories: General Medicine NewsTweet
-
Mashup Score: 54
Most of the published data with trastuzumab deruxtecan (T-DXd) derive from clinical trials with selected populations and little representation of US patients. Limited real-world data are available.
Source: www.esmoopen.comCategories: General Medicine NewsTweet-
Important report @ESMO_Open from @PTarantinoMD - real world outcomes with T-DXd show much shorter rwPFS in pts previously treated with sacituzumab govitecan. With so many ADCs now using topoisomerase inhibitors, can we truly sequence these drugs? https://t.co/bxuwB9f6Gc
-
-
Mashup Score: 62Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis - 7 day(s) ago
Lung cancer (LC) incidence and mortality have changed significantly over the past few decades, yet the disease remains the leading cause of cancer-related deaths worldwide. LC ranks first in incidence and mortality among men and second among women. In 2022, the estimated global age-standardized incidence rate (ASIR, per 105) was 32.1 for men and 16.2 for women, while age-standardized mortality rate (ASMR, per 105) was 24.8 for men and 9.8 for women. The highest incidence and mortality rates were reported in Turkey among men (ASIR: 68.0 and ASMR: 66.3) and in Hungary (ASIR: 35.0 and ASMR: 28.9) among women [1].
Source: www.lungcancerjournal.infoCategories: General Medicine NewsTweet-
Global trends in lung cancer reported @LungCaJournal. Notable for general increase in lung cancer incidence and mortality in women, esp France (incidence) and Norway (mortality). Increases noted in some countries despite decrease in tobacco use (Japan). https://t.co/NreGJrKXRk
-
-
Mashup Score: 29
Sugemalimab with chemotherapy showed a superior long-term overall survival benefit compared with placebo with chemotherapy, as a first-line treatment for patients with NSCLC with no known sensitising EGFR, ALK, ROS1, or RET genomic alterations. These results underscore the efficacy of sugemalimab plus platinum-based chemotherapy as a standard first-line treatment option for both squamous and non-squamous metastatic NSCLC while maintaining a manageable safety profile.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
Updated 4-year outcomes from phase III GEMSTONE-302 trial (sugemalimab vs placebo with 1L chemo in NSCLC) @TheLancetOncol. Outcomes favor sugemalimab: PFS 9m vs 4.9m (HR 0.49), OS 25.2m vs 16.9m (HR 0.68), 4y OS 32.1% vs 17.3%. https://t.co/zRcqb9ai5l
-
-
Mashup Score: 83
Invasive mucinous adenocarcinoma (IMA) is a type of primary lung adenocarcinoma characterized by tumor cells that exhibit a goblet or columnar cell morphology and contain large amounts of intracytoplasmic mucin. IMA is a relatively rare tumor, accounting for 3-10% of lung adenocarcinomas 1 2 3. Approximately 55% of cases occur in females 3, and there is a tendency for the disease to be more common in non-smokers or light smokers 4 .
Source: www.clinical-lung-cancer.comCategories: General Medicine NewsTweet-
Genomic landscape of resected invasive mucinous adenocarcinoma @ClinicalLung (n=107). KRAS mutations common - in 70.1% of cases - with NRG1 fusions identified in 9.2% of cases. Best identified with RNA seq. https://t.co/1kpVjA9md7
-
-
Mashup Score: 44
Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of PD-(L)1 inhibitors by inhibiting protumor inflammation.
Source: www.jtocrr.orgCategories: General Medicine NewsTweet-
Results from negative phase 2 CANOPY-N trial @JTOonline. Pts with resectable NSCLC randomized to neoadjuvant canakinumab (anti IL-1β), pembrolizumab, or both. Canakinumab MPR 3%, pembro MPR 17%, combo MPR 17%. Disappointing but glad results published. https://t.co/gWZ1wN6IqT
-
-
Mashup Score: 114
The PHAROS primary analysis showed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report results after 18 months of additional follow-up.
Source: www.jto.orgCategories: General Medicine NewsTweet-
Update from the Phase 2 PHAROS Study of encorafenib + binimetinib in #BRAF V600E NSCLC @JTOonline. As 1L therapy, RR 75%, DOR 40m, PFS 30m, 3y OS rate 53%. In previously treated, RR 46%, DOR 16.7m, PFS 9.3m, OS 22.7m, 3y OS 29%. https://t.co/RP8Lq8omsM
-
-
Mashup Score: 9
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard 25 June | 15:30–17:30 CEST/ 08:30–10:30 CDT/ 14:30–16:30 BST Agenda available soon
Source: us06web.zoom.usCategories: General Medicine NewsTweet-
RT @OncoAlert: You're invited to join the Post #ASCO25 #LungCancer 🫁Highlights webinar, Register here👉 https://t.co/MIQP43N0UT ⭐️June 25,…
-
-
Mashup Score: 77
Microabstract: Osimertinib showed PFS of 20.1 months and OS of 42.0 months in EGFRm+ NSCLC, comparable to those of the FLAURA trial. Adverse events included pneumonitis (16.7%), QT prolongation (4.6%), and ejection fraction decrease (2.6%). Events such as pneumonitis (17 cases) and cardiotoxicity (7 cases) were observed after 1 year, underscoring the need for long-term safety monitoring.
Source: www.clinical-lung-cancer.comCategories: General Medicine NewsTweet-
Real world outcomes in Japan with 1L osimertinib monotherapy in #EGFR NSCLC (OSI-FACT-OS) @ClinicalLung. With median f/u of 37m, mPFS 20.1m and mOS 42m. All grade pneumonitis rate 16.7% (G3+ was 5.2%), uncommon after first year on therapy. https://t.co/EqeNVxhbOc
-
-
Mashup Score: 27
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard 25 June | 15:30–17:30 CEST/ 08:30–10:30 CDT/ 14:30–16:30 BST Agenda available soon
Source: us06web.zoom.usCategories: General Medicine NewsTweet-
Join Dr. @NReguart, Dr. @nicogirardcurie and me on Wednesday, June 25 at 9:30am EST (15:30 CEST) for this free webinar with @VJOncology where we discuss the lung cancer highlights from #ASCO25. Global perspectives on emerging data! https://t.co/gNBYTZubVa https://t.co/9KoY1bE0ua
-
Surgical outcomes from AEGEAN (neoadjuvant durvalumab + chemo for NSCLC) now @JTOonline from @t_mitsudomi. Same rate of surgery for both arms (81%) with higher R0 resection rates with durvalumab (95% vs 91%) and no diff in time to adjuvant treatment. https://t.co/YK2kZhgqY3